PharmaCyte Biotech
PMCB
31 hedge funds and large institutions have $12M invested in PharmaCyte Biotech in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 3 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
36% more capital invested
Capital invested by funds: $8.79M → $12M (+$3.17M)
5.09% more ownership
Funds ownership: 18.93% → 24.02% (+5.1%)
3% less funds holding
Funds holding: 32 → 31 (-1)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
79% less call options, than puts
Call options by funds: $390K | Put options by funds: $1.85M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
+$2.23M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.32M |
| 3 |
CAG
Csenge Advisory Group
Clearwater,
Florida
|
+$506K |
| 4 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$98.1K |
| 5 |
SC
Shay Capital
New York
|
+$83.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.25M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$157K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$80.2K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$37.9K |
| 5 |
FIA
FNY Investment Advisers
New York
|
-$34K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| – | -$4.25K | -1,680 | -97% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$2.69K | -1,064 | -92% |
|
28
Wells Fargo
San Francisco,
California
| – | -$3 | -1 | -0.7% |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$134 | +53 | +54% |
|
PMCB Hedge Fund Activity: Q3 2022 in Review
31 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q3 2022, worth a combined $12M — up 36% from $8.79M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PMCB and 2 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 9 added.
The largest buyer was Ayrton Capital, adding an estimated $2.23M. The largest seller was Sabby Management, cutting an estimated $1.25M.
- 31 institutional investors held PharmaCyte Biotech (PMCB) as of Q3 2022, down from 32 in Q2 2022.
- Funds reported $12M of PharmaCyte Biotech stock for Q3 2022, up 36% quarter-over-quarter.
- 2 funds opened new PharmaCyte Biotech positions in Q3 2022 and 3 closed out, a net change of -1 holder.
- The largest PharmaCyte Biotech buyer in Q3 2022 was Ayrton Capital, an estimated $2.23M added.
- The largest PharmaCyte Biotech seller in Q3 2022 was Sabby Management, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2022.